Post pregnancy contraception

被引:20
作者
Makins, Anita [1 ,2 ]
Cameron, Sharon [3 ]
机构
[1] Oxford Univ Hosp NHS Trust, Obstet & Gynaecol, Oxford, England
[2] FIGO, FIGO PPIUD Initiat, London, England
[3] Chalmers Ctr, 2a Chalmers St, Edinburgh EH3 9ES, Midlothian, Scotland
关键词
Post pregnancy; Post-partum; Post-abortion contraception and family planning; POSTPARTUM ETONOGESTREL IMPLANT; MEDICAL ABORTION EFFICACY; DELAYED INSERTION; CONTINUATION RATES; IMMEDIATE; WOMEN; TERMINATION; HEALTH; IMPACT; BARRIERS;
D O I
10.1016/j.bpobgyn.2020.01.004
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Ovulation resumes as quickly as 21 days after birth in a non-fully breastfeeding woman. Traditionally, contraceptive services have been offered 6 weeks post-partum. This is far from ideal and results in unnecessary abortions or inadequate birth spacing which both carry an increased risk of morbidity to mother and potential newborn as well as costs to the health care service. It is now clear that contraception should be discussed during the pregnancy so that the method of choice can be offered immediately post pregnancy prior to discharge from hospital. Long acting reversible contraceptive methods such as implants and IUDs are highly effective as they are user-independent. Large studies have demonstrated that they can be safely inserted during the immediate post-partum period with no increase in complication rates. Policy makers should strive to overcome barriers to offering quality post pregnancy contraceptive services. (C) 2020 Published by Elsevier Ltd.
引用
收藏
页码:41 / 54
页数:14
相关论文
共 73 条
[1]   Operations research to add postpartum family planning to maternal and neonatal health to improve birth spacing in Sylhet District, Bangladesh [J].
Ahmed, Salahuddin ;
Norton, Maureen ;
Williams, Emma ;
Ahmed, Saifuddin ;
Shah, Rasheduzzaman ;
Begum, Nazma ;
Mungia, Jaime ;
LeFevre, Amnesty ;
Al-Kabir, Ahmed ;
Winch, Peter J. ;
McKaig, Catharine ;
Baquia, Abdullah H. .
GLOBAL HEALTH-SCIENCE AND PRACTICE, 2013, 1 (02) :262-276
[2]  
[Anonymous], 2018, Family Planning: A Global Handbook for Providers, V2018
[3]  
[Anonymous], 2015, Medical eligibility criteria for contraceptive use, V5th
[4]  
[Anonymous], 2015, COCHRANE DATABASE SY
[5]  
[Anonymous], 2012, Global Health Policy Summit, Report of the Maternal Health Working Group
[6]  
[Anonymous], 2003, Safe abortion: Technical and policy guidance for health systems
[7]   Immediate versus delayed postpartum use of levonorgestrel contraceptive implants: a randomized controlled trial in Uganda [J].
Averbach, Sarah ;
Kakaire, Othman ;
Kayiga, Herbert ;
Lester, Felicia ;
Sokoloff, Abby ;
Byamugisha, Josaphat ;
Dehlendorf, Christine ;
Steinauer, Jody .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2017, 217 (05) :568.e1-568.e7
[8]   HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial [J].
Baeten, Jared M. ;
Donnell, Deborah ;
Gichangi, Peter B. ;
Heller, Kate B. ;
Hofmeyr, G. Justus ;
Kiarie, James ;
Mastro, Timothy D. ;
Morrison, Charles S. ;
Mugo, Nelly R. ;
Nanda, Kavita ;
Palanee-Phillips, Thesla ;
Pleaner, Melanie ;
Rees, Helen ;
Scoville, Caitlin W. ;
Shears, Kathleen ;
Steyn, Petrus S. ;
Taylor, Douglas ;
Thomas, Katherine K. ;
Welch, Julia D. ;
Justman, Jessica ;
Nhlabatsi, Zelda ;
Bukusi, Elizabeth A. ;
Onono, Maricianah ;
Louw, Cheryl ;
Bekker, Linda-Gail ;
Nair, Gonasagrie ;
Smit, Jennifer ;
Hofmeyr, G. Justus ;
Singata-Madliki, Mandisa ;
Smit, Edendale Jennifer ;
Palanee-Phillips, Thesla ;
Selepe, Raesibe Agnes Pearl ;
Sibiya, Sydney ;
Ahmed, Khatija ;
Kasaro, Margaret Phiri ;
Stringer, Jeffrey .
LANCET, 2019, 394 (10195) :303-313
[9]   The impact of using nurses to perform postpartum intrauterine device insertions in Kalyani Hospital, India [J].
Bhadra, Banasree ;
Burman, Sougata K. ;
Purandare, Chittaranjan N. ;
Divakar, Hema ;
Sequeira, Thelma ;
Bhardwaj, Ajey .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2018, 143 :33-37
[10]   Hormonal contraceptive use before hCG remission does not increase the risk of gestational trophoblastic neoplasia following complete hydatidiform mole: a historical database review [J].
Braga, A. ;
Maesta, I. ;
Short, D. ;
Savage, P. ;
Harvey, R. ;
Seckl, M. J. .
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2016, 123 (08) :1330-1335